BACKGROUND: Intradialytic parenteral nutrition (IDPN) is used infrequently to correct hypoalbuminemia in maintenance hemodialysis (MHD) patients. We hypothesized that the severity of baseline hypoalbuminemia correlates with the success rate of IDPN therapy in MHD patients. METHODS: In a prospective and contemporary cohort of 196 hypoalbuminemic MHD patients who received IDPN through Pentec Health (Boothwyn, PA), predictors of IDPN response were examined using multivariate logistic regression. RESULTS: Of 196 hypoalbuminemic MHD patients, 134 had severe hypoalbuminemia, defined as a baseline serum albumin level of less than 3.0 g/dL. The average period of IDPN therapy was 5.8 +/- 2.4 months, S.D. The baseline level of serum albumin was lower in MHD patients who responded to IDPN (2.68 +/- 0.47 g/dL, S.D.). A multivariate logistic regression analysis adjusted the associations for age, gender, diabetes, and IDPN time. The presence of severe hypoalbuminemia (serum albumin, <3.0 g/dL) at baseline was associated with a 2.5 times higher chance of responding to IDPN (95% confidence interval, 1.3 to 4.9; P = .006). The same severe hypoalbuminemia was associated with a 3.5 times increased likelihood of serum albumin correction by at least 0.5 g/dL (95% confidence interval, 1.8 to 6.8; P < .001). CONCLUSIONS: Improvement of hypoalbuminemia occurs in most hypoalbuminemic MHD patients who receive IDPN therapy. The likelihood and magnitude of the response to IDPN are associated with the severity of baseline hypoalbuminemia. These associations need to be verified in controlled trials.
BACKGROUND: Intradialytic parenteral nutrition (IDPN) is used infrequently to correct hypoalbuminemia in maintenance hemodialysis (MHD) patients. We hypothesized that the severity of baseline hypoalbuminemia correlates with the success rate of IDPN therapy in MHD patients. METHODS: In a prospective and contemporary cohort of 196 hypoalbuminemic MHD patients who received IDPN through Pentec Health (Boothwyn, PA), predictors of IDPN response were examined using multivariate logistic regression. RESULTS: Of 196 hypoalbuminemic MHD patients, 134 had severe hypoalbuminemia, defined as a baseline serum albumin level of less than 3.0 g/dL. The average period of IDPN therapy was 5.8 +/- 2.4 months, S.D. The baseline level of serum albumin was lower in MHD patients who responded to IDPN (2.68 +/- 0.47 g/dL, S.D.). A multivariate logistic regression analysis adjusted the associations for age, gender, diabetes, and IDPN time. The presence of severe hypoalbuminemia (serum albumin, <3.0 g/dL) at baseline was associated with a 2.5 times higher chance of responding to IDPN (95% confidence interval, 1.3 to 4.9; P = .006). The same severe hypoalbuminemia was associated with a 3.5 times increased likelihood of serum albumin correction by at least 0.5 g/dL (95% confidence interval, 1.8 to 6.8; P < .001). CONCLUSIONS: Improvement of hypoalbuminemia occurs in most hypoalbuminemic MHD patients who receive IDPN therapy. The likelihood and magnitude of the response to IDPN are associated with the severity of baseline hypoalbuminemia. These associations need to be verified in controlled trials.
Authors: Noël J M Cano; Denis Fouque; Hubert Roth; Michel Aparicio; Raymond Azar; Bernard Canaud; Philippe Chauveau; Christian Combe; Maurice Laville; Xavier M Leverve Journal: J Am Soc Nephrol Date: 2007-07-26 Impact factor: 10.121
Authors: Kamyar Kalantar-Zadeh; Ryan D Kilpatrick; Noriko Kuwae; Charles J McAllister; Harry Alcorn; Joel D Kopple; Sander Greenland Journal: Nephrol Dial Transplant Date: 2005-06-14 Impact factor: 5.992
Authors: Kamyar Kalantar-Zadeh; Joel D Kopple; Ryan D Kilpatrick; Charles J McAllister; Christian S Shinaberger; David W Gjertson; Sander Greenland Journal: Am J Kidney Dis Date: 2005-09 Impact factor: 8.860
Authors: Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz Journal: N Engl J Med Date: 2005-07-21 Impact factor: 91.245
Authors: Kamyar Kalantar-Zadeh; Ryan D Kilpatrick; Charles J McAllister; Sander Greenland; Joel D Kopple Journal: Hypertension Date: 2005-02-07 Impact factor: 10.190
Authors: Kamyar Kalantar-Zadeh; Kevin C Abbott; Abdulla K Salahudeen; Ryan D Kilpatrick; Tamara B Horwich Journal: Am J Clin Nutr Date: 2005-03 Impact factor: 7.045
Authors: Vanessa A Ravel; Miklos Z Molnar; Elani Streja; Jun Chul Kim; Alla Victoroff; Jennie Jing; Debbie Benner; Keith C Norris; Csaba P Kovesdy; Joel D Kopple; Kamyar Kalantar-Zadeh Journal: J Nutr Date: 2013-05-22 Impact factor: 4.798
Authors: Kamyar Kalantar-Zadeh; Noël J Cano; Klemens Budde; Charles Chazot; Csaba P Kovesdy; Robert H Mak; Rajnish Mehrotra; Dominic S Raj; Ashwini R Sehgal; Peter Stenvinkel; T Alp Ikizler Journal: Nat Rev Nephrol Date: 2011-05-31 Impact factor: 28.314